The Incidence of Congenital Defects in the Descendants of Mothers Taking Medication in the First Trimester in the Czech Republic in the Period of 1996-2001;Výskyt Vrozených Vad u Děti v Potomstvu Matek Uživajících v I. Trimestru Gravidity Medikaci v Česke Republice v Období 1996-2001

Ceska Gynekologie

Volumn 68, Issue 6, 2003, Pages 401-419

  Sipek A ^a,b   Gregor, V ^b,c   Velebil, P ^a,b   Horacek J ^b,c   Masatova W ^d   Svetnicova K ^c  

^a INSTITUTE FOR THE CARE OF MOTHER AND CHILD   (Czech Republic)

^b IPVZ   (Czech Republic)

^c FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^d Institute of Health Information and Statistics of the Czech Republic   (Czech Republic)

Author keywords

Congenital defect; Czech Republic; Incidence; Population teratology; Teratogen

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; TERATOGENIC AGENT; VASODILATOR AGENT;

CHILD; CONGENITAL DISORDER; CONTROLLED STUDY; CZECH REPUBLIC; DATA ANALYSIS; DATA BASE; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC RISK; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; POPULATION RESEARCH; PRENATAL DRUG EXPOSURE; REVIEW; TERATOLOGY;

EID: 0842325292     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Beghi, E., Annegers, J. F.: The Collaborative Group for the Pregnancy Registries in Epilepsy. Pregnancy registries in epilepsy. Epilepsia, 42, 2001, 11, s. 1422-1425.
2. Briggs, G. B., Freeman, R. K., Yaffe, S. J.: Drugs in pregnancy and lactation. Sixt Edition. Lippincot Williams & Wilkins, 2002.
3. Buehler, B. A., Delimont, D., van Waes, M., Finnell, R. H.: Prenatal prediction of risk of the fetal hydantoin syndrome. N. Engl. J. Med., 31, 322,1990, 22, s. 1567-1572.
4. Burdan, F.: Prenatal effects of acetylsalicylic acid. Pol. Merkuriusz Lek., 11, 2001, Aug. 62, s. 182-186.
5. Canger, R., Battino, D., Canevini, M. P., Fumarola, C., Guidolin, L., Vignoli, A., Mamoli, D., Palmier, C., Molteni, F., Granata, T., Hassibi, P., Zamperini, P., Pardi, G., Avanzini, G.: Malformations in offspring of women with epilepsy: a prospective study. Epilepsia, 40, 1999, s. 1231-1236.
6. Czeizel, A. E., Rockenbauer, M., Sorensen, H. T., Olsen, J.: Nitrofurantoin and congenital abnormalities. Eur. J. Obstet. Gynecol. Reprod. Biol., Mar. 95, 2001, 1, s. 119-126.
7. Dalens, B., Raynaud, E. J., Gaulme, J.: Teratogenicity of valproic acid. J. Pediatr., 97, 1980, s. 332-333.
8. Dansky, L., Andermann, E., Andermann, F.: Major congenital malformations on the offspring of epileptic patients: genetics and environmental risk factors. In: Epilepsy, Pregnancy and the Child. Proceedings of a workshop held in Berlin, 1980. New York: Raven Press, 1981.
9. De Bandt, M., Palazzo, E., Belmatoug, N., M'Bappe, P., Hayem, G., Kahn, M. F., Meyer, O.: Outcome of pregnancies in lupus: experience at one center. Ann. Med. Interne (Paris), 151, 2000, 2, s. 87-92.
10. De Santis, M., Carducci, B., Cavaliere, A. F., De Santis, L., Straface, G., Caruso, A.: Drug-induced congenital defects: strategies to reduce the incidence. Drug Saf., 24, 2001, 12, s. 889-901.
11. De Smet, L., Debeer, P.: Fetal hydantoin syndrome with unilateral atypical cleft hand: additional evidence for vascular disruption. Genet Couns., 13, 2002, 2, s. 157-161.
12. Dean, J. C., Moore, S. J., Osborne, A., Howe, J., Turnpenny, P. D.: Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin. Genet., 56, 1999, 3, s. 216-220.
13. Dessens, A. B., Cohen-Kettenis, P. T., Mellenbergh, G. J., Koppe, J. G., Poll, N. E., Boer, K.: Association of prenatal phenobarbital and phenytoin exposure with genital anomalies and menstrual disorders. Teratology, 64, 2001, 4, s. 181-188.
14. Dichter, M. A., Brodie, M. J.: New Antiepileptic drugs. N. Engl. J. Med., 334, 1996, s. 1583-1590.
15. Gigantelli, J. W., Braddock, S. R., Johnson, L. N.: Blepharoptosis and central nervous system abnormalities in combined valproate and hydantoin embryopathy. Ophthal. Plast. Reconstr. Surg., 16, 2000, 1, s. 52-54.
16. Glaxo Welcome. Lamotrigine Pregnancy Registry. Interim Report (1 September through 31 March 2000). Glaxo Welcome, July 2000.
17. Godbole, K. G., Gambhir, P. S., Deshpande, A. S., Kurlekar, S. U., Phadke, M. A.: Fetal hydantoin syndrome with rheumatic valvular heart disease. Indian J. Pediatr., 66, 1999, 2, s. 290-293.
18. Gregg, N. M.: Congenital cataract following German measles in the mother Trans. Ophthalmol. Soc., 35, 1941, 3.
19. Grech, V., Vella, C.: Atrioventricular septal defect with separate right and left atrioventricular valvar orifices in a patient with foetal hydantoin syndrome. Cardiol. Young, 9, 1999, 1, s. 73-74.
20. Hanson, J. W.: Fetal hydantoin effects. In: Sever, J. L., Brent, R. L. (Eds.): Teratogen Update: Environmentally Induced Birth Defect Risks. New York, Alan R. Liss, 1986.
21. Heinonen, O. P., Slone, S., Shapiro, s. Birth Defects and Drugs in Pregnancy. Littleton, M. M. A.: Publishing Sciences Group, 372, 1977.
22. Hernandez-Diaz, S., Werler, M. M., Walker, A. M., Mitchell, A. A.: Folic acid antagonists during pregnancy and the risk of birth defects. E. Engl. J. Med., 30, 2000, 22, s. 1608-1614.
23. Hill, R. B.: Teratogenesis and antiepileptic drugs. N. J. Engl. Med., 289, 1973, s. 1089-1090.
24. Holmes, L. B., Harvey, E. A., Coull, B. A., Huntington, K. B., Khosbin, S., Hayes, A. M., Ryan, L. M.: The teratogenicity of anticonvulsant drugs. N. Engl. J. Med., 334, 2001, s. 1132-1138.
25. Holmes, L. B., Harvey, E. A.: Holoprosencephaly and the teratogenicity of anticonvulsants. Teratology, 49, 1994, 2, s. 82.
26. Huong, D. L., Wechsler, B., Bletry, O., Vauthier-Brouzes, D., Lefebvre, G., Piette, J. C.: A study of 75 pregnancies in patients with antiphospholipid syndrome. J. Rheumatol., 28, 2001, 9, s. 2025-2030.
27. Janz, D., Fuchs, V.: Are anti-epileptic drugs harmful when given during pregnancy? German Med. Monogr., 9, 1964, s. 20-23.
28. Janz, D.: The teratogenic risk of antiepileptic drugs. Epilepsia, 16, 1975, s. 159-169.
29. Jones, K. L., Lacro, R. V., Johnson, K. A., Adams, J.: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N. J. Engl. J. Med., 320, 1989, s. 1661-1666.
30. Kaneko, S., Battino, D., Andermann, E., Wada, K., Kan, R., Takeda, A., Nakane, Y., Ogawa, Y., Avanzini, G., Fumarola, C., Granata, T., Molteni, F., Pardi, G., Minotti, L., Canger, R., Dansky, L., Oguni, M., Lopes-Cendas, I., Sherwin, A., Andermann, E, Seni, M. H., Okada, M., Teranishi, T.: Congenital malformations due to antiepileptic drugs. Epilepsy Res., Feb., 33, 1999, 2-3, s. 145-158.
31. Kotzot, D., Weigl, J., Huk, W., Rott, H. D.: Hydantoin syndrome with holoprosencephaly: a possible rare teratogenic effect. Teratology, 48, 1993, 1, s. 15-19.
32. Koup, J. R., Rose, J. Q., Cohen, M. E.: Ethosuximide pharmacokinetics in pregnant patient and her newborn. Epilepsie, 19, 1978, s. 535.
33. Lenz, W.: A short history of thalidomide embryopathy. Teratology, 38, 1988. s- 203.
34. McBride, W. G.: Thalidomide and congenital abnormalities. Lancet, 2, 1961, s. 1358.
35. Meyer, J. G.: Teratogenic risk of anticonvulsants and the effects on pregnancy and birth. Eur. Neurol., 10, 1979, s. 179-190.
36. Moore, S. J., Turnpenny, P., Quinn, A., Lloyd, D. J., Montgomery, T., Dean, J. C.: A clinical study of 57 children with fetal anticonvulsant syndromes. J. Med. Genet., 37, 2000, 7, s. 489-497.
37. Morell, M. J.: The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcomes. Epilepsia, 37, Suppl. 6, 1996, s. S34-S34.
38. Myhree, S. A., Williams, R.: Teratogenic effects associated with maternal primidone therapy. J. Pediatr., 99, 1981, s. 160-162.
39. Nakane, Y., Okuma, T., Takahashi, R. et al.: Multi-institucional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia, 21, 1980, s. 663-680.
40. Pauzner, R., Dulitzki, M., Langevitz, P., Livneh, A., Kenett, R., Many, A.: Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb. Haemost., 86, 2001, 6, s. 1379-1384.
41. Persaud, T. V. N., Moore, K. L.: Zrození člověka. Embryologie s klinickým zaměněním. ISV Nakladatelství, Praha, 2002.
42. Roche Laboratories. Products information. Klonopin. Roche Laboratories, 2000.
43. Rosa, F.: Holoprosencephaly and antiepileptic exposures. Teratology, 51, 1995, 4, s. 230.
44. Rudd, N. L., Freedom, R. M.: A possible primidone embryopathy. J. Pediatr., 94, 1979, s. 835-837.
45. Sachs, Lothar: Aplied Statistics, Second Edition. Springer Verlag New York, 1984.
46. Samren, E. B., van Duijn, C. M., Christiaens, G. C., Hofman, A., Lindhout, D.: Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann. Neurol., 46, 1999, 5, s. 739-746.
47. Saxen, I.: Association between oral clefts and drugs during pregnancy. Int. J. Epidemiol., 4, 1975, s. 37-44.
48. Sibai, B. M., Anderson, G. D.: Pregnancy outcome of intensive therapy in severe hypertension in first trimester. Obstet. Gynecol., 67, 1986, s. 517-522.
49. Slone, D., Heinonen, O. P., Kaufman, D. W., Siskind, V., Monson, R. R., Shapiro, S.: Aspirin and congenital malformation. Lancet, 1, 1976, s. 381-394.
50. Sorensen, H. T., Johnsen, S. P., Larsen, H., Pedersen, L., Nielsen, G. L., Moller, M.: Birth outcomes in pregnant women treated with low-molecular-weight heparin. Acta Obstet. Gynecol. Scand., 79, 2000, 8, s. 655-659.
51. Thomas, D., Buchanan, N.: Teratogenic effects of anticonvulsants. J. Pediatr., 99, 1981, s. 163.
52. Werler, M. M., Mitchell, A. A., Shapiro, S.: The relation of aspirin use during the first trimesterb of pregnancy to congenital cardiac defects. N. Engl. J. Med., 321, 1989, s. 1639-1642.
53. Wesseling, J., Van Driel, D., Heymans, H. S., Rosendaal, F. R., Geven-Boere, L. M., Smrkovsky, M., Touwen, B. C., Sauer, P. J., Van der Veer, E.: Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb. Haemost., 85, 2001, 4, s. 609-613.
54. Wilton, L. V., Pearce, G. L., Martin, R. M., Mackay, F. J., Mann, R. D.: The outcomes of pregnancy in women exposed to newly market drugs in general practice in England. Br. J. Obstet. Gynaecol., 105, 1998, s. 882-889.
55. Zierler, S., Rothman, K. J.: Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N. Engl. J. Med., 313, 1985, s. 347-352.
56. Zierler, S.: Maternal drugs and congenital heart disease. Obstet. Gynecol., 65, 1985, s. 155-165.